Improved sensitivity of computed tomography towards iodine and gold nanoparticle contrast agents via iterative reconstruction methods

Bernstein, Ally Leigh; Dhanantwari, Amar; Jurcova, Martina; Cheheltani, Rabee; Naha, Pratap C.; Ivanc, Thomas B.; Shefer, E.; Cormode, David P.

doi:10.1038/srep26177

Cited by 43 publications

(40 citation statements)

References 40 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We expect that more information on cell labeling optimization combined with improvements in CT technology and reconstruction software 14,123 will continue to improve detection of labeled cells in CT imaging via higher sensitivity and reduced radiation dose, facilitating the growing interest in using CT for cell tracking purposes.…”

Section: Ct Cell Trackingmentioning

confidence: 99%

Use of Nanoparticle Contrast Agents for Cell Tracking with Computed Tomography

Kim¹,

Chhour²,

Hsu³

et al. 2017

Bioconjugate Chem.

115

118

View full text Add to dashboard Cite

Efforts to develop novel cell-based therapies originated with the first bone marrow transplant on a leukemia patient in 1956. Preclinical and clinical examples of cell-based treatment strategies have shown promising results across many disciplines in medicine, with recent advances in immune cell therapies for cancer producing remarkable response rates, even in patients with multiple treatment failures. However, cell-based therapies suffer from inconsistent outcomes, motivating the search for tools that allow monitoring of cell delivery and behavior in vivo. Noninvasive cell imaging techniques, also known as cell tracking, have been developed to address this issue. These tools can allow real-time, quantitative, and long-term monitoring of transplanted cells in the recipient, providing insight on cell migration, distribution, viability, differentiation, and fate, all of which play crucial roles in treatment efficacy. Understanding these parameters allows the optimization of cell choice, delivery route, and dosage for therapy and advances cell-based therapy for specific clinical uses. To date, most cell tracking work has centered on imaging modalities such as MRI, radionuclide imaging, and optical imaging. However, X-ray computed tomography (CT) is an emerging method for cell tracking that has several strengths such as high spatial and temporal resolution, and excellent quantitative capabilities. The advantages of CT for cell tracking are enhanced by its wide availability and cost effectiveness, allowing CT to become one of the most popular clinical imaging modalities and a key asset in disease diagnosis. In this review, we will discuss recent advances in cell tracking methods using X-ray CT in various applications, in addition to predictions on how the field will progress.

show abstract

Section: Ct Cell Trackingmentioning

confidence: 99%

Use of Nanoparticle Contrast Agents for Cell Tracking with Computed Tomography

Kim¹,

Chhour²,

Hsu³

et al. 2017

Bioconjugate Chem.

115

118

View full text Add to dashboard Cite

show abstract

“…Iodinated polymeric micelles are mainstream contrast agents for visualizing the vasculature due to their prolonged circulation than free molecules . Recent reports have involved the use of gold NPs for targeting atherosclerotic plaques, due to their tunable physicochemical properties, biocompatibility, and ability to attenuate X‐rays. In 2013, by labeling LDL with gold nanocrystals and injecting them into mice, Allijn et al probed the athero–nano interactions of lipoprotein by three different imaging modalities, including CT, spectral CT, and fluorescence imaging.…”

Section: Preclinical Biomedical Applicationsmentioning

confidence: 99%

Recent Advances in Managing Atherosclerosis via Nanomedicine

Chan

Zhang

Cheng

et al. 2017

Small

View full text Add to dashboard Cite

Atherosclerosis, driven by chronic inflammation of the arteries and lipid accumulation on the blood vessel wall, underpins many cardiovascular diseases with high mortality rates globally, such as stroke and ischemic heart disease. Engineered bio-nanomaterials are now under active investigation as carriers of therapeutic and/or imaging agents to atherosclerotic plaques. This Review summarizes the latest bio-nanomaterial-based strategies for managing atherosclerosis published over the past five years, a period marked by a rapid surge in preclinical applications of bio-nanomaterials for imaging and/or treating atherosclerosis. To start, the biomarkers exploited by emerging bio-nanomaterials for targeting various components of atherosclerotic plaques are outlined. In addition, recent efforts to rationally design and screen for bio-nanomaterials with the optimal physicochemical properties for targeting plaques are presented. Moreover, the latest preclinical applications of bio-nanomaterials as carriers of imaging, therapeutic, or theranostic agents to atherosclerotic plaques are discussed. Finally, a mechanistic understanding of the interactions between bio-nanomaterials and the plaque ("athero-nano" interactions) is suggested, the opportunities and challenges in the clinical translation of bio-nanomaterials for managing atherosclerosis are discussed, and recent clinical trials for atherosclerotic nanomedicines are introduced.

show abstract

“…13 Nanoparticles consisting of noble metals (e.g., Ag, Au, and Pt) have been reported as CT contrast agents. 14,15 Paramagnetic Gd or Mn-based materials and ferromagnetic iron oxides have been developed as T 1 or T 2weighted magnetic resonance imaging (MRI) contrast agents. 16 When using chemical strategies to obtain high performance of nanoplatform-based CAs, it is important to control the composition and/or structure of the nanoparticles.…”

Section: Introductionmentioning

confidence: 99%